Form S-1/A
VACCINEX, INC. filed this Form S-1/A on 08/08/2018
Document Outline
Entire Document (4101.6 KB)
Subdocument 1 - S-1/A - S-1/A
Page 1 - As filed with the Securities and Exchange Commission on August 7, 2018.
Page 2 - CALCULATION OF REGISTRATION FEE
Page 3 - PRELIMINARY PROSPECTUS
Page 4 - TABLE OF CONTENTS
Page 5 - PROSPECTUS SUMMARY
Page 6 - Vaccinex Product Pipeline
Page 7 - Other Product Candidates
Page 8 - VX25
Page 9 - Emerging Growth Company
Page 10 - The Offering
Page 11 - N/A
Page 12 - Summary Consolidated Financial Data
Page 13 - N/A
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - We will require additional capital to finance our operations, which may not be available to us on ac
Page 17 - Our ability to continue as a going concern will require us to obtain additional financing to fund ou
Page 18 - Risks Related to Our Business and Industry
Page 19 - If we experience delays in clinical testing, we will be delayed in obtaining approval of our product
Page 20 - We may not successfully identify, develop or commercialize potential product candidates.
Page 21 - We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in
Page 22 - We are subject to multiple manufacturing risks, any of which could substantially increase our costs
Page 23 - Even if our product candidates receive regulatory approval, they may still face future development a
Page 24 - One of the indications we are pursuing for our lead product candidate VX15 is for the treatment of H
Page 25 - Our failure to obtain regulatory approval in international jurisdictions would prevent us from marke
Page 26 - Our competitors may develop and market products or services that are less expensive, more effective,
Page 27 - We may not be able to achieve the benefits or synergistic effects of VX15 in combination with other
Page 28 - We do not currently have any sales, marketing or distribution experience or infrastructure and may r
Page 29 - Current and future legislation may increase the difficulty and cost for commercialization of our pro
Page 30 - If we are able to successfully commercialize any of our product candidates and if we participate in
Page 31 - Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
Page 32 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 33 - We depend on key personnel for our continued operations and future success and a loss of certain key
Page 34 - We depend on third-party manufacturers for the manufacture of drug substance and drug product for cl
Page 35 - Collaborations may require us to relinquish important rights to and control over the development of
Page 36 - N/A
Page 37 - We may not be able to protect our intellectual property rights throughout the world.
Page 38 - Changes in patent law and legal precedent concerning patents could diminish the value of patents in
Page 39 - We may become involved in lawsuits to protect or enforce our intellectual property rights, which cou
Page 40 - Third parties may initiate legal proceedings against us alleging that we infringe their intellectual
Page 41 - Our inability to protect our confidential information and trade secrets would harm our business and
Page 42 - We have broad discretion in the use of the net proceeds from this offering and may not use them effe
Page 43 - If securities or industry analysts do not publish research or publish inaccurate or unfavorable rese
Page 44 - We will incur significant increased costs as a result of operating as a public company, and our mana
Page 45 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 46 - N/A
Page 47 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 48 - IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY
Page 49 - USE OF PROCEEDS
Page 50 - N/A
Page 51 - DIVIDEND POLICY
Page 52 - CAPITALIZATION
Page 53 - N/A
Page 54 - DILUTION
Page 55 - N/A
Page 56 - N/A
Page 57 - SELECTED CONSOLIDATED FINANCIAL DATA
Page 58 - N/A
Page 59 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 60 - Financial Overview
Page 61 - General and Administrative. Our general and administrative expenses consist primarily of compensatio
Page 62 - Interest Expense
Page 63 - Operating Expenses
Page 64 - Comparison of the Years Ended December 31, 2016 and 2017
Page 65 - Interest Expense
Page 66 - Cash Flows
Page 67 - Investing Activities. Cash used in investing activities during the years ended December 31, 2016 and
Page 68 - Convertible Promissory Notes
Page 69 - Contractual Obligations
Page 70 - Foreign Currency Risk
Page 71 - Stock-Based Compensation
Page 72 - Common Stock Valuations
Page 73 - Income Taxes and Net Operating Loss Carryforwards
Page 74 - Derivative Liabilities
Page 75 - Recent Accounting Pronouncements Not Yet Adopted
Page 76 - BUSINESS
Page 77 - Vaccinex Product Pipeline
Page 78 - Huntington s Disease
Page 79 - N/A
Page 80 - Background on the Immune System and Antibodies
Page 81 - Our SEMA4D Antibody Platform
Page 82 - Collaboration and IST Agreements
Page 83 - Emory
Page 84 - Figure 1. SEMA4D Expression Concentrated at Tumor Growing Edge
Page 85 - Figure 3. Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor
Page 86 - Figure 5. SEMA4D Gradient at Invasive Tumor Margin Regulates Migration and
Page 87 - Figure 6. Anti-SEMA4D Treatment Shifts the Balance of Cytokines and Chemokines in the Tumor Microenv
Page 88 - Figure 7A. Combination Treatment with Anti-CTLA-4 and Anti-SEMA4D in a Colorectal Tumor
Page 89 - Current Approaches to Cancer Treatment
Page 90 - Our Approach to a Combination Therapy in Cancer
Page 91 - Figure 8. Treatment of PLXNB1 and ErbB-2 Double Positive Mammary Carcinoma with Anti-SEMA4D Delays T
Page 92 - Completed Phase 1 Clinical Trials
Page 93 - Ongoing and Planned Phase 1b/2 Clinical Trials
Page 94 - VX15 in Huntington s Disease
Page 95 - Figure 10. VX15 Promotes Migration of Oligodendrocyte Precursor Cells
Page 96 - Current Approaches to the Treatment of Huntington s Disease
Page 97 - Our Approach to Huntington s Disease
Page 98 - Figure 12. VX15 Treatment Significantly Inhibits Cortical and Corpus Callosum Degeneration in Brains
Page 99 - Figure 13. VX15 May Improve Spatial Memory in the YAC128 Mouse Model
Page 100 - Figure 14. MRI: Mean Change from Baseline in Regions of Frontal and Parietal Cortex
Page 101 - Figure 15. FDG-PET: Mean Change from Baseline in Regions of Frontal and Parietal Cortex
Page 102 - Our Approach to Antibody Discovery
Page 103 - Discovery Collaborations with Third Parties
Page 104 - Catalent Pharma Solutions
Page 105 - BVX20 for Multiple Sclerosis
Page 106 - Intellectual Property
Page 107 - SEMA4D Antibody Platform and VX15
Page 108 - ActivMAb Antibody Discovery Platform
Page 109 - ActivMAb Platform Patents. Three patent families covering the ActivMAb platform are wholly owned by
Page 110 - Patent Protection
Page 111 - Trade Secret Protection
Page 112 - Preclinical Testing. Before testing any compound in human subjects, a sponsor must develop extensive
Page 113 - The BLA Process
Page 114 - N/A
Page 115 - Postmarketing Commitments. The FDA may require, or companies may pursue, additional clinical trials
Page 116 - Advertising and Promotion. The FDA and other federal and state agencies regulate the labeling, marke
Page 117 - N/A
Page 118 - Federal and State Fraud and Abuse and Data Privacy and Security Laws and Regulations
Page 119 - Healthcare Reform
Page 120 - N/A
Page 121 - Regulation Outside of the United States
Page 122 - N/A
Page 123 - VX3
Page 124 - N/A
Page 125 - MANAGEMENT
Page 126 - Alan L. Crane has served as a member of our board of directors since March 2003. Since February 2002
Page 127 - Bala S. Manian, Ph.D. has served as a member of our board of directors since December 2004. Dr. Mani
Page 128 - Raymond E. Watkins has served as our Senior Vice President and Chief Operating Officer since January
Page 129 - Independence of the Board of Directors and Board Committees
Page 130 - Role of the Board in Risk Oversight
Page 131 - Audit Committee
Page 132 - Code of Business Conduct and Ethics
Page 133 - EXECUTIVE AND DIRECTOR COMPENSATION
Page 134 - Other Benefits
Page 135 - Stock Options. The 2018 Plan will authorize our compensation committee to grant incentive stock opti
Page 136 - Performance Awards. The 2018 Plan will permit the grant of performance-based stock and cash awards.
Page 137 - Amendment; Termination. Our compensation committee may amend or terminate the 2018 Plan at any time;
Page 138 - Share Reserve. As of June 30, 2018, stock options to purchase a total of 22,500 shares of our common
Page 139 - Director Compensation
Page 140 - Limitation of Liability and Indemnification Agreements
Page 141 - N/A
Page 142 - CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
Page 143 - Series D Redeemable Convertible Preferred Stock Financing
Page 144 - Participation in this Offering
Page 145 - Policies and Procedures Regarding Transactions with Related Persons
Page 146 - PRINCIPAL STOCKHOLDERS
Page 147 - N/A
Page 148 - DESCRIPTION OF CAPITAL STOCK
Page 149 - Fully Paid and Nonassessable
Page 150 - Incidental Registration Rights
Page 151 - Section 203 of the Delaware General Corporation Law
Page 152 - Transfer Agent and Registrar
Page 153 - SHARES ELIGIBLE FOR FUTURE SALE
Page 154 - Rule 701
Page 155 - MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES TO NON-U.S. HOLDERS
Page 156 - Distributions
Page 157 - Information Reporting Requirements and Backup Withholding
Page 158 - N/A
Page 159 - UNDERWRITING
Page 160 - N/A
Page 161 - Electronic Delivery of Preliminary Prospectus
Page 162 - Canada
Page 163 - France
Page 164 - Sweden
Page 165 - N/A
Page 166 - LEGAL MATTERS
Page 167 - VACCINEX, INC.
Page 168 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 169 - VACCINEX, INC.
Page 170 - VACCINEX, INC.
Page 171 - VACCINEX, INC.
Page 172 - VACCINEX, INC.
Page 173 - VACCINEX, INC.
Page 174 - VACCINEX, INC.
Page 175 - VACCINEX, INC.
Page 176 - VACCINEX, INC.
Page 177 - VACCINEX, INC.
Page 178 - VACCINEX, INC.
Page 179 - VACCINEX, INC.
Page 180 - VACCINEX, INC.
Page 181 - VACCINEX, INC.
Page 182 - VACCINEX, INC.
Page 183 - VACCINEX, INC.
Page 184 - VACCINEX, INC.
Page 185 - VACCINEX, INC.
Page 186 - VACCINEX, INC.
Page 187 - VACCINEX, INC.
Page 188 - VACCINEX, INC.
Page 189 - VACCINEX, INC.
Page 190 - VACCINEX, INC.
Page 191 - VACCINEX, INC.
Page 192 - VACCINEX, INC.
Page 193 - VACCINEX, INC.
Page 194 - VACCINEX, INC.
Page 195 - VACCINEX, INC.
Page 196 - VACCINEX, INC.
Page 197 - VACCINEX, INC.
Page 198 - VACCINEX, INC.
Page 199 - VACCINEX, INC.
Page 200 - VACCINEX, INC.
Page 201 - VACCINEX, INC.
Page 202 - VACCINEX, INC.
Page 203 - VACCINEX, INC.
Page 204 - VACCINEX, INC.
Page 205 - 3,333,000 Shares
Page 206 - PART II
Page 207 - Item 15. Recent Sales of Unregistered Securities.
Page 208 - Convertible Promissory Note Financings
Page 209 - Item 17. Undertakings.
Page 210 - INDEX TO EXHIBITS
Page 211 - N/A
Page 212 - SIGNATURES
Page 213 - N/A
Subdocument 2 - EX-3.4 - EX-3.4
Page 1 - Exhibit 3.4
Page 2 - N/A
Subdocument 3 - EX-3.18 - EX-3.18
Page 1 - Exhibit 3.18
Page 2 - N/A
Subdocument 4 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - SECTION 1
Page 6 - Director means any member of the Board who is not an employee of Vaccinex or a Parent or Subsidiary.
Page 7 - 1933 Act means the Securities Act of 1933, as amended.
Page 8 - Stock Grant means Stock granted under Section 11.
Page 9 - SECTION 4
Page 10 - SECTION 6
Page 11 - SECTION 8
Page 12 - SECTION 9
Page 13 - N/A
Page 14 - SECTION 10
Page 15 - N/A
Page 16 - SECTION 11
Page 17 - N/A
Page 18 - SECTION 12
Page 19 - SECTION 13
Page 20 - SECTION 14
Page 21 - N/A
Page 22 - SECTION 16
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - IN WITNESS WHEREOF, Vaccinex has caused its duly authorized officer to execute this Plan this 29th d
Subdocument 5 - EX-10.4(A) - EX-10.4(A)
Page 1 - Exhibit 10.4(a)
Page 2 - N/A
Subdocument 6 - EX-23.1 - EX-23.1
Page 1 - N/A